The global vaccine market size reached USD 59.8 Billion in 2024. Looking forward, the analyst expects the market to reach USD 136.5 Billion by 2033, exhibiting a growth rate (CAGR) of 9.12% during 2025-2033. The implementation of stringent regulations promoting the adoption of vaccination among individuals, several advances in biotechnology and vaccine development techniques, and the growing health awareness among the population about the importance of vaccination are some of the major factors propelling the market.
Vaccines are essential tools in public health, designed to prevent and control the spread of infectious diseases. They are essentially biological preparations that stimulate the immune system to recognize and fight specific pathogens, such as bacteria or viruses. They contain weakened or inactivated forms of the target pathogen or pieces of it, known as antigens. When administered, vaccination mimic an infection, prompting the immune system to produce antibodies and develop immune memory. Additionally, it ensures immune system to swiftly mount a defense, effectively preventing illness or reducing its severity, when the individual is exposed to the actual pathogen.
The market is primarily driven by the growing health concerns among individuals. In addition, the recent onset of the coronavirus disease (COVID-19) pandemic raised awareness among individuals regarding the importance of the product in safeguarding public health, thus augmenting the market growth. Moreover, the development of novel vaccine technologies, such as mRNA products are transforming the industry by offering faster and precise vaccine development capabilities, addressing emerging threats effectively, thus representing another major growth-inducing factor.
Besides this, pharmaceutical companies are expanding their vaccine portfolios to include vaccinations for various diseases beyond the traditional ones which opened new markets and revenue streams, thus accelerating the sales demand. Along with this, several government initiatives including vaccination drives, public awareness campaigns, and funding for vaccine research to curb the spread of diseases are propelling the market growth. Furthermore, the ongoing vaccine research and development investment (R&D) in public and private sectors ensures a robust pipeline of new products, thus creating a positive market outlook.
Besides this, companies are providing clear and comprehensive information about their products, including potential side effects and contraindications which empowers individuals to make informed decisions about vaccination, thus accelerating the product adoption rate. Along with this, various governments and healthcare authorities are implementing various incentive programs including subsidies, public awareness campaigns, and mandates in some cases encouraging the adoption of vaccination, thus propelling the market growth.
Moreover, several advancements in recombinant deoxyribonucleic acid (DNA) technology allowed for the creation of recombinant vaccinations, stimulating enhanced immune response without causing the disease itself which is effective in preventing infectious diseases, including hepatitis B and human papillomavirus, thus representing another major growth-induing factor. Furthermore, the application of synthetic biology techniques is also contributing to several innovations, allowing scientists to design and synthesize vaccine components with precision, for the development of novel vaccinations against challenging pathogens, thus creating a positive market outlook.
Moreover, the dissemination of accurate information through various channels, including healthcare providers, government agencies, and the media to safeguard public health, which represents another major growth-inducing factor. Besides this, the rise of social media and digital platforms played a significant part in providing information about vaccinations, enabling individuals to access reliable resources and engage in informed discussions.
Conjugate products are gaining popularity due to their effectiveness in preventing bacterial infections. They are designed to elicit a strong immune response and are particularly used for diseases such as haemophilus influenzae type B (Hib) and streptococcus pneumoniae.
Moreover, inactivated and subunit products are widely used for viral diseases, such as influenza, hepatitis B, and human papillomavirus (HPV) which contain components of the pathogen, ensuring safety while still providing immunity, thus representing another major growth-inducing factor. Besides this, Live attenuated vaccines are created from weakened forms of pathogens and are effective against diseases such as measles, mumps, and rubella which are essential in disease eradication programs, thus accelerating the sales demand.
Along with this, recombinant products use genetic engineering to create vaccinations against diseases such as hepatitis B and human papillomavirus and offer potential for customization and efficacy, thus propelling the market growth. Also, toxoid vaccinations are employed for bacterial diseases including diphtheria and tetanus due to their long-lasting immunity benefits, thus augmenting the market growth.
The pediatrics segment is driven by the growing emphasis on immunization, thus influencing the market growth. Moreover, governments and healthcare organizations are preventing childhood diseases, leading to increasing vaccination programs and investments in pediatric vaccine research, thus contributing to market growth.
Moreover, several advancements in vaccine technology made it possible to develop safer and more effective vaccinations for children, resulting in a steady stream of new vaccinations tailored specifically for pediatric populations, representing another major growth-inducing factor.
Additionally, the COVID-19 pandemic underscored the importance of vaccinations for children. Efforts to vaccinate children against the virus further increase the role of pediatrics in the vaccine industry, thus propelling the market growth.
The market is driven by the growing incidences of bacterial diseases, caused by various bacteria such as Streptococcus pneumoniae and Haemophilus influenzae. In addition, the increasing development of effective vaccinations to prevent these infections is augmenting the market growth.
Furthermore, several advancements in vaccine technology are improving bacterial disease vaccinations. Along with this, several innovations in research and development (R&D) yielded vaccinations that are effective and safe for widespread use which are designed to stimulate the body's immune response, thereby conferring immunity against bacterial pathogens, thus propelling the market growth.
Intramuscular administration involves injecting vaccinations directly into the muscle tissue which offers several advantages. In addition, muscles have an abundant blood supply, allowing for efficient uptake and distribution of the vaccine components leading to improved immune response, thus influencing the market growth. Along with this, IM injections often require larger needles, which can facilitate the administration of vaccinations with thicker formulations or those containing adjuvants, thus augmenting the market growth.
Moreover, subcutaneous administration involves injecting vaccinations into the fatty tissue just beneath the skin which is preferred for products that are well-suited for slower, sustained release into the bloodstream, thus representing another major growth-inducing factor. It is less invasive and typically uses smaller needles, making it a preferred choice among individuals who may be apprehensive about needles.
Multivalent offers a streamlined approach to immunization by combining antigens from different pathogens into a single vaccine, which reduces the number of injections required, minimizing discomfort for patients and simplifying vaccination schedules, thus augmenting the market growth.
Furthermore, multivalent vaccinations are efficient in preventing several diseases. For instance, combination vaccinations such as the measles, mumps, and rubella (MMR) vaccinations are eliminating these diseases in many regions, resulting in extensive research and development (R&D) efforts in the field, thus propelling the market growth.
Along with this, multivalent vaccinations offer substantial advantages, as the production, distribution, and administration of a single vaccine covering multiple diseases are more efficient and economical compared to individual vaccinations for each pathogen, thus accelerating the product adoption rate among healthcare systems and patients.
Preventive vaccinations are designed to proactively protect individuals from contracting specific diseases. They achieve this by stimulating the immune system to produce antibodies that recognize and neutralize pathogens, such as viruses or bacteria, should the individual be exposed to them in the future has proven to be highly effective in reducing the incidence and severity of various illnesses.
Moreover, it has immense success in eradicating or controlling life-threatening diseases. Some historical examples include the near-eradication of smallpox through vaccination and the significant reduction in polio cases which are essential in fighting against infectious diseases. Furthermore, the rapid development and distribution of products to combat the virus and save countless lives are propelling the market growth.
The hospital industry is driven by its strategic position as a primary healthcare provider. In addition, hospitals serve as the frontline of defense against infectious diseases, making them the ideal setting for vaccine dissemination which possesses the necessary infrastructure, medical personnel, and resources to efficiently handle the storage, distribution, and administration of products, thus propelling the market growth.
Furthermore, hospitals are essential in vaccination advocacy and education. They are trusted sources of healthcare information, and their healthcare professionals serve as product advocates through patient consultations, seminars, and informational campaigns. Along with this, hospitals are promoting the importance of vaccination, contributing to higher vaccination rates and public awareness.
Along with this, hospitals also engage in product research and development (R&D), partnering with pharmaceutical companies and research institutions to conduct clinical trials and assess vaccination efficacy, thus contributing to market growth.
Hospital pharmacies are located at the heart of healthcare facilities which ensures that vaccinations are easily accessible to healthcare professionals and patients. Hospitals are often the first point of contact for individuals seeking vaccination, whether it's for routine immunizations or during public health emergencies.
Moreover, hospital pharmacies have the infrastructure and trained staff necessary to handle and administer products safely while adhering to strict quality control and storage protocols, ensuring the integrity and efficacy of vaccinations throughout the distribution process, thus representing another major growth-inducing factor. This reliability and commitment to maintaining the cold chain are essential for preserving the potency of products.
Along with this, hospital pharmacies benefit from established relationships with healthcare providers and government agencies responsible for vaccination programs which allows for seamless coordination in vaccination procurement, distribution, and administration, thus propelling the market growth. Also, hospitals serve as vaccination hubs during mass immunization campaigns, further solidifying their role in the market.
The Asia Pacific market is driven by the growing pharmaceutical and biotechnology sector. In addition, several countries such as India and China are investing heavily in the development of their healthcare infrastructure, research capabilities, and manufacturing capacities, allowing them to produce vaccination at scale, often at a lower cost than their Western counterparts. thus, contributing to the market growth.
Additionally, the rising pool of skilled scientists, researchers, and healthcare professionals is augmenting the market growth. These experts are driving innovation and ensuring the quality and safety of vaccinations produced in the region. Furthermore, the region offers ample opportunities for clinical trials and testing, allowing for the accelerated development of new products, thus accelerating the sales demand.
Apart from this, the strategic partnerships and collaborations among pharmaceutical companies in the region are facilitating technology transfer, knowledge sharing, and access to critical resources, strengthening the region's position in the market.
Moreover, companies are establishing thought leadership through content marketing and thought-provoking research reports which help in showcasing expertise and attract clients who seek industry insights. Besides this, they are focusing on client satisfaction and building long-term relationships by providing personalized services and tailored solutions based on client requirements that enhance trust and loyalty.
The market research report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided.
Vaccines are essential tools in public health, designed to prevent and control the spread of infectious diseases. They are essentially biological preparations that stimulate the immune system to recognize and fight specific pathogens, such as bacteria or viruses. They contain weakened or inactivated forms of the target pathogen or pieces of it, known as antigens. When administered, vaccination mimic an infection, prompting the immune system to produce antibodies and develop immune memory. Additionally, it ensures immune system to swiftly mount a defense, effectively preventing illness or reducing its severity, when the individual is exposed to the actual pathogen.
The market is primarily driven by the growing health concerns among individuals. In addition, the recent onset of the coronavirus disease (COVID-19) pandemic raised awareness among individuals regarding the importance of the product in safeguarding public health, thus augmenting the market growth. Moreover, the development of novel vaccine technologies, such as mRNA products are transforming the industry by offering faster and precise vaccine development capabilities, addressing emerging threats effectively, thus representing another major growth-inducing factor.
Besides this, pharmaceutical companies are expanding their vaccine portfolios to include vaccinations for various diseases beyond the traditional ones which opened new markets and revenue streams, thus accelerating the sales demand. Along with this, several government initiatives including vaccination drives, public awareness campaigns, and funding for vaccine research to curb the spread of diseases are propelling the market growth. Furthermore, the ongoing vaccine research and development investment (R&D) in public and private sectors ensures a robust pipeline of new products, thus creating a positive market outlook.
Vaccine Market Trends/Drivers:
The implementation of stringent regulations promoting the adoption of vaccination
The market is driven by the enforcement of stringent regulations aimed at promoting vaccination among individuals. In addition, the growing emphasis on vaccine safety and efficacy is augmenting the market growth. Moreover, manufacturers adhere to rigorous testing and quality control measures to ensure that products meet the highest standards of safety, resulting in rising investment in research and development (R&D) to create products that prevent diseases effectively and have minimal adverse effects, thus representing another major growth-inducing factor.Besides this, companies are providing clear and comprehensive information about their products, including potential side effects and contraindications which empowers individuals to make informed decisions about vaccination, thus accelerating the product adoption rate. Along with this, various governments and healthcare authorities are implementing various incentive programs including subsidies, public awareness campaigns, and mandates in some cases encouraging the adoption of vaccination, thus propelling the market growth.
Several advances in biotechnology and vaccine development techniques
The market is driven by several remarkable advances in biotechnology and vaccine development techniques. It is transforming the way vaccinations are designed and manufactured which is contributing to the development of highly effective and targeted vaccinations. In addition, the utilization of genomics and molecular biology in vaccine development led scientists to decode the genetic information of pathogens with unprecedented speed and precision, enabling them to identify potential vaccine candidates more efficiently, resulting in the development of products against emerging diseases such as COVID-19, thus augmenting the market growth.Moreover, several advancements in recombinant deoxyribonucleic acid (DNA) technology allowed for the creation of recombinant vaccinations, stimulating enhanced immune response without causing the disease itself which is effective in preventing infectious diseases, including hepatitis B and human papillomavirus, thus representing another major growth-induing factor. Furthermore, the application of synthetic biology techniques is also contributing to several innovations, allowing scientists to design and synthesize vaccine components with precision, for the development of novel vaccinations against challenging pathogens, thus creating a positive market outlook.
The growing awareness about the importance of vaccination
The market is driven by the growing health awareness among individuals regarding the importance of vaccination. In addition, the recent onset of the coronavirus disease (COVID-19) pandemic raised public awareness about the value of vaccination, thus augmenting the market growth. Along with this, manufacturers are developing and distributing vaccinations to combat the virus while focusing on vaccine efficacy, safety, and accessibility, thus propelling the market growth.Moreover, the dissemination of accurate information through various channels, including healthcare providers, government agencies, and the media to safeguard public health, which represents another major growth-inducing factor. Besides this, the rise of social media and digital platforms played a significant part in providing information about vaccinations, enabling individuals to access reliable resources and engage in informed discussions.
Vaccine Industry Segmentation:
This report provides an analysis of the key trends in each segment of the global vaccine market report, along with forecasts at the global, regional, and country levels for 2025-2033. Our report has categorized the market based on technology, patient type, indication, route of administration, product type, treatment type, end user, and distribution channel.Breakup by Technology:
- Conjugate Vaccines
- Inactivated and Subunit Vaccines
- Live Attenuated Vaccines
- Recombinant Vaccines
- Toxoid Vaccines
- Others
Conjugate products are gaining popularity due to their effectiveness in preventing bacterial infections. They are designed to elicit a strong immune response and are particularly used for diseases such as haemophilus influenzae type B (Hib) and streptococcus pneumoniae.
Moreover, inactivated and subunit products are widely used for viral diseases, such as influenza, hepatitis B, and human papillomavirus (HPV) which contain components of the pathogen, ensuring safety while still providing immunity, thus representing another major growth-inducing factor. Besides this, Live attenuated vaccines are created from weakened forms of pathogens and are effective against diseases such as measles, mumps, and rubella which are essential in disease eradication programs, thus accelerating the sales demand.
Along with this, recombinant products use genetic engineering to create vaccinations against diseases such as hepatitis B and human papillomavirus and offer potential for customization and efficacy, thus propelling the market growth. Also, toxoid vaccinations are employed for bacterial diseases including diphtheria and tetanus due to their long-lasting immunity benefits, thus augmenting the market growth.
Breakup by Patient Type:
- Pediatric
- Adult
Pediatric patients hold the largest share of the market
A detailed breakup and analysis of the market based on the patient type has also been provided in the report. This includes pediatric and adult. According to the report, pediatrics accounted for the largest market share.The pediatrics segment is driven by the growing emphasis on immunization, thus influencing the market growth. Moreover, governments and healthcare organizations are preventing childhood diseases, leading to increasing vaccination programs and investments in pediatric vaccine research, thus contributing to market growth.
Moreover, several advancements in vaccine technology made it possible to develop safer and more effective vaccinations for children, resulting in a steady stream of new vaccinations tailored specifically for pediatric populations, representing another major growth-inducing factor.
Additionally, the COVID-19 pandemic underscored the importance of vaccinations for children. Efforts to vaccinate children against the virus further increase the role of pediatrics in the vaccine industry, thus propelling the market growth.
Breakup by Indication:
- Bacterial Diseases
- Meningococcal Disease
- Pneumococcal Disease
- Diphtheria/Tetanus/Pertussis (DPT)
- Tuberculosis
- Haemophilus Influenzae (Hib)
- Typhoid
- Others
- Viral Diseases
- Hepatitis
- Influenza
- Human Papillomavirus (HPV)
- Measles/Mumps/Rubella (MMR)
- Rotavirus
- Herpes Zoster
- Varicella
- Japanese Encephalitis
- Rubella
- Polio
- Rabies
- Dengue
- Others
Bacterial diseases presently account for the largest market share
A detailed breakup and analysis of the market based on the indication has also been provided in the report. This includes bacterial diseases (meningococcal disease, pneumococcal disease, diphtheria/tetanus/pertussis (DPT), tuberculosis, haemophilus influenza (Hib), typhoid, and others) and viral diseases (hepatitis, influenzae, human papillomavirus (HPV), measles/mumps/rubella (MMR), rotavirus, herpes zoster, varicella, Japanese encephalitis, rubella, polio, rabies, dengue, and others). According to the report, bacterial diseases accounted for the largest market share.The market is driven by the growing incidences of bacterial diseases, caused by various bacteria such as Streptococcus pneumoniae and Haemophilus influenzae. In addition, the increasing development of effective vaccinations to prevent these infections is augmenting the market growth.
Furthermore, several advancements in vaccine technology are improving bacterial disease vaccinations. Along with this, several innovations in research and development (R&D) yielded vaccinations that are effective and safe for widespread use which are designed to stimulate the body's immune response, thereby conferring immunity against bacterial pathogens, thus propelling the market growth.
Breakup by Route of Administration:
- Intramuscular and Subcutaneous Administration
- Oral Administration
- Others
Intramuscular and subcutaneous administration represents the leading segment
The report has provided a detailed breakup and analysis of the market based on the route of administration. This includes intramuscular and subcutaneous administration, oral administration, and others. According to the report, intramuscular and subcutaneous administration accounted for the largest market share.Intramuscular administration involves injecting vaccinations directly into the muscle tissue which offers several advantages. In addition, muscles have an abundant blood supply, allowing for efficient uptake and distribution of the vaccine components leading to improved immune response, thus influencing the market growth. Along with this, IM injections often require larger needles, which can facilitate the administration of vaccinations with thicker formulations or those containing adjuvants, thus augmenting the market growth.
Moreover, subcutaneous administration involves injecting vaccinations into the fatty tissue just beneath the skin which is preferred for products that are well-suited for slower, sustained release into the bloodstream, thus representing another major growth-inducing factor. It is less invasive and typically uses smaller needles, making it a preferred choice among individuals who may be apprehensive about needles.
Breakup by Product Type:
- Multivalent Vaccine
- Monovalent Vaccine
Multivalent vaccine represent the most used product type
The report has provided a detailed breakup and analysis of the market based on the product type. This includes multivalent vaccine and monovalent vaccine. According to the report, multivalent vaccine accounted for the largest market share.Multivalent offers a streamlined approach to immunization by combining antigens from different pathogens into a single vaccine, which reduces the number of injections required, minimizing discomfort for patients and simplifying vaccination schedules, thus augmenting the market growth.
Furthermore, multivalent vaccinations are efficient in preventing several diseases. For instance, combination vaccinations such as the measles, mumps, and rubella (MMR) vaccinations are eliminating these diseases in many regions, resulting in extensive research and development (R&D) efforts in the field, thus propelling the market growth.
Along with this, multivalent vaccinations offer substantial advantages, as the production, distribution, and administration of a single vaccine covering multiple diseases are more efficient and economical compared to individual vaccinations for each pathogen, thus accelerating the product adoption rate among healthcare systems and patients.
Breakup by Treatment Type:
- Preventive Vaccine
- Therapeutic Vaccine
Preventive vaccine currently dominates the market
The report has provided a detailed breakup and analysis of the market based on the treatment type. This includes preventive vaccine and therapeutic vaccine. According to the report, preventive vaccine accounted for the largest market share.Preventive vaccinations are designed to proactively protect individuals from contracting specific diseases. They achieve this by stimulating the immune system to produce antibodies that recognize and neutralize pathogens, such as viruses or bacteria, should the individual be exposed to them in the future has proven to be highly effective in reducing the incidence and severity of various illnesses.
Moreover, it has immense success in eradicating or controlling life-threatening diseases. Some historical examples include the near-eradication of smallpox through vaccination and the significant reduction in polio cases which are essential in fighting against infectious diseases. Furthermore, the rapid development and distribution of products to combat the virus and save countless lives are propelling the market growth.
Breakup by End User:
- Hospitals
- Clinics
- Vaccination Centers
- Academic and Research Institutes
- Others
Hospitals hold the largest share of the market
A detailed breakup and analysis of the market based on the end user has also been provided in the report. This includes hospitals, clinics, vaccination centers, academic and research institutes, and others. According to the report, hospitals accounted for the largest market share.The hospital industry is driven by its strategic position as a primary healthcare provider. In addition, hospitals serve as the frontline of defense against infectious diseases, making them the ideal setting for vaccine dissemination which possesses the necessary infrastructure, medical personnel, and resources to efficiently handle the storage, distribution, and administration of products, thus propelling the market growth.
Furthermore, hospitals are essential in vaccination advocacy and education. They are trusted sources of healthcare information, and their healthcare professionals serve as product advocates through patient consultations, seminars, and informational campaigns. Along with this, hospitals are promoting the importance of vaccination, contributing to higher vaccination rates and public awareness.
Along with this, hospitals also engage in product research and development (R&D), partnering with pharmaceutical companies and research institutions to conduct clinical trials and assess vaccination efficacy, thus contributing to market growth.
Breakup by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Institutional Sales
- Others
Hospital pharmacies presently account for the largest market share
A detailed breakup and analysis of the market based on the distribution channel has also been provided in the report. This includes hospital pharmacies, retail pharmacies, institutional sales, and others. According to the report, hospital pharmacies accounted for the largest market share.Hospital pharmacies are located at the heart of healthcare facilities which ensures that vaccinations are easily accessible to healthcare professionals and patients. Hospitals are often the first point of contact for individuals seeking vaccination, whether it's for routine immunizations or during public health emergencies.
Moreover, hospital pharmacies have the infrastructure and trained staff necessary to handle and administer products safely while adhering to strict quality control and storage protocols, ensuring the integrity and efficacy of vaccinations throughout the distribution process, thus representing another major growth-inducing factor. This reliability and commitment to maintaining the cold chain are essential for preserving the potency of products.
Along with this, hospital pharmacies benefit from established relationships with healthcare providers and government agencies responsible for vaccination programs which allows for seamless coordination in vaccination procurement, distribution, and administration, thus propelling the market growth. Also, hospitals serve as vaccination hubs during mass immunization campaigns, further solidifying their role in the market.
Breakup by Region:
- North America
- United States
- Canada
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
- Turkey
- GCC Countries
- Israel
- Others
Asia Pacific exhibits a clear dominance in the market
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Asia Pacific accounted for the largest market share.The Asia Pacific market is driven by the growing pharmaceutical and biotechnology sector. In addition, several countries such as India and China are investing heavily in the development of their healthcare infrastructure, research capabilities, and manufacturing capacities, allowing them to produce vaccination at scale, often at a lower cost than their Western counterparts. thus, contributing to the market growth.
Additionally, the rising pool of skilled scientists, researchers, and healthcare professionals is augmenting the market growth. These experts are driving innovation and ensuring the quality and safety of vaccinations produced in the region. Furthermore, the region offers ample opportunities for clinical trials and testing, allowing for the accelerated development of new products, thus accelerating the sales demand.
Apart from this, the strategic partnerships and collaborations among pharmaceutical companies in the region are facilitating technology transfer, knowledge sharing, and access to critical resources, strengthening the region's position in the market.
Competitive Landscape:
At present, key players in the market are taking strategic initiatives to strengthen their positions in the competitive landscape of the market research and consulting services industry. These actions are vital for maintaining their relevance and authority in the field. They are embracing advanced technologies including artificial intelligence, machine learning, and data analytics which help in delivering more accurate and actionable insights, that is highly valued by clients.Moreover, companies are establishing thought leadership through content marketing and thought-provoking research reports which help in showcasing expertise and attract clients who seek industry insights. Besides this, they are focusing on client satisfaction and building long-term relationships by providing personalized services and tailored solutions based on client requirements that enhance trust and loyalty.
The market research report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided.
Some of the key players in the market include:
- Abbott Laboratories
- Astellas Pharma Inc.
- AstraZeneca Plc
- Bharat Biotech International
- Bavarian Nordic A/S
- CSL Limited
- Daiichi Sankyo Company Limited
- Emergent BioSolutions Inc.
- GlaxoSmithKline Plc
- Inovio Pharmaceuticals Inc.
- Johnson & Johnson
- Merck & Co. Inc.
- Mitsubishi Tanabe Pharma Corporation (Mitsubishi Chemical Holdings Corporation)
- Novavax Inc.
- Panacea Biotec Ltd.
- Pfizer Inc.
- Sanofi Pasteur SA (Sanofi SA)
- Serum Institute of India Pvt. Ltd.
- Takeda Pharmaceutical Company Limited.
Recent Developments:
- In September 2020, the Serum Institute of India Pvt. Ltd., partnered with Gavi and the Bill & Melinda Gates Foundation to accelerate the production and distribution of an additional 100 million doses of COVID-19 vaccines that are safe and effective.
- In April 2023, Pfizer Inc., announced data from phase 3 trials of its RSV shots. The trial conducted in adult patients demonstrated that the shot was 67% more effective in preventing infections with two related symptoms and 86% effective in case of severe disease. The successful approval of this vaccine will make it the first product in the RSV market.
- In June 2022, GlaxoSmithKline Plc officially submitted a Biologics License Application (BLA) to the United States Food and Drug Administration (USFDA) for their experimental vaccine known as PRIORIX, which originally registered in Germany, has received licenses from more than 100 countries.
Key Questions Answered in This Report:
- What was the size of the global vaccine market in 2024?
- What is the expected growth rate of the global vaccine market during 2025-2033?
- What are the key factors driving the global vaccine market?
- What has been the impact of COVID-19 on the global vaccine market?
- What is the breakup of the global vaccine market based on the patient type?
- What is the breakup of the global vaccine market based on the indication?
- What is the breakup of the global vaccine market based on the route of administration?
- What is the breakup of the global vaccine market based on the product type?
- What is the breakup of the global vaccine market based on the treatment type?
- What is the breakup of the global vaccine market based on the end user?
- What is the breakup of the global vaccine market based on the distribution channel?
- What are the key regions in the global vaccine market?
- Who are the key players/companies in the global vaccine market?
Table of Contents
1 Preface3 Executive Summary18 Price Analysis19 Major Drivers and Challenges
2 Scope and Methodology
4 Introduction
5 Global Vaccine Market
6 Market Breakup by Technology
7 Market Breakup by Patient Type
8 Market Breakup by Indication
9 Market Breakup by Route of Administration
10 Market Breakup by Product Type
11 Market Breakup by Treatment Type
12 Market Breakup by End User
13 Market Breakup by Distribution Channel
14 Market Breakup by Region
15 SWOT Analysis
16 Value Chain Analysis
17 Porters Five Forces Analysis
20 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Abbott Laboratories
- Astellas Pharma Inc.
- AstraZeneca Plc
- Bharat Biotech International
- Bavarian Nordic A/S
- CSL Limited
- Daiichi Sankyo Company Limited
- Emergent BioSolutions Inc.
- GlaxoSmithKline Plc
- Inovio Pharmaceuticals Inc.
- Johnson & Johnson
- Merck & Co. Inc.
- Mitsubishi Tanabe Pharma Corporation (Mitsubishi Chemical Holdings Corporation)
- Novavax Inc.
- Panacea Biotec Ltd.
- Pfizer Inc.
- Sanofi Pasteur SA (Sanofi SA)
- Serum Institute of India Pvt. Ltd.
- Takeda Pharmaceutical Company Limited
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 144 |
| Published | April 2025 |
| Forecast Period | 2024 - 2033 |
| Estimated Market Value ( USD | $ 59.8 Billion |
| Forecasted Market Value ( USD | $ 136.5 Billion |
| Compound Annual Growth Rate | 9.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 19 |
